Generic Competition Meets a Pipeline Showcase
Novo Nordisk enters a critical period with Q1 earnings due May 6, a Canadian Ozempic generic launch, stock…
Teen Pill Success Meets Canadian Generic Shock
Novo Nordisk celebrates positive trial results for oral semaglutide in teens while facing first generic Ozempic competition in…
Novo Nordisk’s Hemophilia Breakthrough Fails to Distract From Canadian Generic Blow
Novo Nordisk’s stock slides 41% as Canada approves first generic Ozempic, while promising hemophilia data fails to lift…
Canadian Generic Launch and Q1 Results Loom
Health Canada authorizes Dr. Reddy’s biosimilar semaglutide, threatening Novo Nordisk’s Ozempic revenue as share buyback reaches 3.44 billion…
Novo Nordisk Juggles Pipeline Advances and Generic Threat as Share Buyback Hits $3.44 Billion
Novo Nordisk launches Phase 3 knee OA trial, gains FDA fast-track for heart drug, as first Ozempic generic…
Novo Nordisk’s Teen Pill Breakthrough and Canadian Generic Blow Arrive in the Same Week
Novo Nordisk faces a historic Ozempic generic in Canada while scoring a first-in-class oral GLP-1 win for teens,…
Eli Lilly’s Mounjaro loses ground to Novo Nordisk’s semaglutide, and the slew of cheaper generics
A Mounjaro injection used for weight loss procedures at a clinic in Mumbai, March 31, 2026. | Photo…
Novo Nordisk Faces Generic Onslaught and Dividend Adjustment in Key Market
Novo Nordisk’s semaglutide patent expires in India, sparking generic price war. Stock hits 52-week low while trading ex-dividend,…
Ozempic copies for $14 as the generic GLP-1 era starts in India
At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster…
Novo Nordisk Faces Mounting Pressure as Generic Rival Emerges
The Danish pharmaceutical giant’s commanding position in the weight-loss drug market is under significant threat. Novo Nordisk, already…